ARTICLE

Volume 10,Issue 7

All Issues
Submit to JCNR
Cite this article
2
Citations
2
Views
26 August 2025
The Efficacy of Tongxinluo Capsules in Treating Coronary Heart Disease with Angina Pectoris and Its Impact on Cardiac Function
Ruxin Ji
Show Less
1 Mianzhu Center for Disease Control and Prevention, Mianzhu 618200, Sichuan, China,
JCNR 2025 , 9(8), 21–26; https://doi.org/10.26689/jcnr.v9i8.11700
© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
HTML
Abstract

Objective: To analyze the efficacy of Tongxinluo Capsules in treating coronary heart disease (CHD) with angina pectoris. Methods: A total of 98 patients with CHD and angina pectoris admitted between May 2022 and May 2025 were enrolled and randomly divided into a control group and an experimental group, with 49 cases each. The control group was treated with atorvastatin + clopidogrel, while the experimental group received atorvastatin + clopidogrel + Tongxinluo Capsules. Clinical efficacy, cardiac function, angina attack frequency and duration, and adverse reactions were compared between the two groups. Results: The experimental group showed higher clinical efficacy than the control group (P < 0.05). Cardiac function in the experimental group was superior to that of the control group (P < 0.05). The duration and frequency of angina attacks in the experimental group were lower than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The use of Tongxinluo Capsules in the clinical treatment of CHD with angina pectoris can improve various clinical indicators, enhance therapeutic efficacy, and promote faster patient recovery.

References
Wang F, Jing J, 2025, Observation on the Efficacy and Safety of Tongxinluo Capsule Combined With Clopidogrel in the Treatment of Coronary Heart Disease and Angina Pectoris With Qi Deficiency and Blood Stasis Syndrome. Chinese and Foreign Women’s Health Research, 2025(1): 59–61.
Chen Z, Huang X, Xiao S, 2023, Effects of Tongxinluo Capsule Combined With Atorvastatin on Blood Lipid Levels and Cardiac Function in Elderly Patients With Coronary Heart Disease. Chinese Journal of Geriatrics, 43(13): 3086–3088.
Cui S, Zhao F, Chang L, et al., 2023, Clinical Efficacy of Tongxinluo Capsule in the Treatment of Stable Angina Pectoris With Qi Deficiency and Blood Stasis Syndrome and Its Effect on Left Ventricular Function. Hebei Journal of Traditional Chinese Medicine, 45(8): 1255–1259.
Shao J, 2022, Study on the Efficacy of Tongxinluo Capsule on Patients After Coronary Heart Disease Intervention and Its Effect on Vascular Endothelial Function and Inflammatory Factors. Guizhou Medicine, 46(2): 294–296.
Kang S, Zhang L, Zhao X, et al., 2025, Effects of Ticagrelor Combined With Atorvastatin on Hemorheological Indicators and Plasma Fibrinogen Levels in Patients With Unstable Angina Pectoris Caused by Coronary Heart Disease. Chinese Journal of Hemorheology, 35(1): 72–76.
Chen J, Wang Y, Lu Z, et al., 2023, Effects of Atorvastatin Combined With Clopidogrel on Blood Lipids, Hemorheology, and Cardiac Function in the Treatment of Coronary Heart Disease and Angina Pectoris. Chinese Journal of Geriatrics, 43(7): 1546–1549.
Wang L, 2025, Study on the Effect of Tongxinluo Capsule Combined With Metoprolol in the Treatment of Coronary Heart Disease and Angina Pectoris. Chinese Journal of Modern Drug Application, 19(2): 71–73.
Share
Back to top
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept